Purpose To evaluate the effect of BLP25 liposome vaccine (L-BLP25) on survival and
toxicity in patients with stage IIIB and IV non–small-cell lung cancer (NSCLC). Secondary …

Purpose To present an updated survival analysis of an open-label, parallel-group, phase IIB
trial of BLP25 liposome vaccine (L-BLP25) in patients with stage IIIB or IV non-small-cell …

Background Previous research suggests the therapeutic cancer vaccine L-BLP25 potentially
provides a survival benefit in patients with locally advanced unresectable stage III non-small …

The identification of tumor-associated/-specific antigens and an increased understanding of
the ways in which antigens are processed and presented has led to a revived interest in …

MUC1 is a mucinous glycoprotein which is overexpressed and under or aberrantly
glycosylated in many human malignancies. MUC1 is associated with cellular transformation …

Active specific immunotherapy with liposomal vaccines targeted to the mucinous carcinoma-
associated glycoprotein MUC1 have shown promising results in animal models. The aim of …

The historical results of cancer vaccination for non-small-cell lung cancer (NSCLC) were
disappointing. In the current decade, however, new insights in the interaction between …

Reports of tumor regression after infection date back as far as 1550 bc. In the twentieth
century, Dr. William Coley, witnessing regression of a malignant tumor in one of his patients …

Lung cancer remains the number one cause of cancer-related death worldwide. Active
cancer immunotherapy is a growing field that is included as one of the most important …

Purpose Belagenpumatucel-L is a nonviral gene-based allogeneic tumor cell vaccine that
demonstrates enhancement of tumor antigen recognition as a result of transforming growth …